vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and TRUSTCO BANK CORP N Y (TRST). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $49.5M, roughly 1.4× TRUSTCO BANK CORP N Y). TRUSTCO BANK CORP N Y runs the higher net margin — 32.9% vs 4.7%, a 28.1% gap on every dollar of revenue. Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (28.1% CAGR vs 6.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
TRUSTCO BANK CORP N Y is a regional U.S. financial holding company that provides a full suite of retail and commercial banking products and services, including personal deposit accounts, mortgage loans, small business financing, and wealth management solutions. It primarily operates across New York, Florida, and several other U.S. states, serving individual consumers and small business client segments.
ADPT vs TRST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $49.5M |
| Net Profit | $3.4M | $16.3M |
| Gross Margin | 73.6% | — |
| Operating Margin | -27.1% | — |
| Net Margin | 4.7% | 32.9% |
| Revenue YoY | 35.1% | — |
| Net Profit YoY | — | 14.1% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | $49.5M | ||
| Q4 25 | $71.7M | $48.2M | ||
| Q3 25 | $94.0M | $47.8M | ||
| Q2 25 | $58.9M | $46.6M | ||
| Q1 25 | $52.4M | $45.3M | ||
| Q4 24 | $47.5M | $43.3M | ||
| Q3 24 | $46.4M | $43.6M | ||
| Q2 24 | $43.2M | $43.4M |
| Q1 26 | $3.4M | $16.3M | ||
| Q4 25 | $-13.6M | $15.6M | ||
| Q3 25 | $9.5M | $16.3M | ||
| Q2 25 | $-25.6M | $15.0M | ||
| Q1 25 | $-29.9M | $14.3M | ||
| Q4 24 | $-33.7M | $11.3M | ||
| Q3 24 | $-32.1M | $12.9M | ||
| Q2 24 | $-46.2M | $12.6M |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — |
| Q1 26 | -27.1% | — | ||
| Q4 25 | -17.8% | 43.7% | ||
| Q3 25 | 10.9% | 44.6% | ||
| Q2 25 | -42.5% | 42.3% | ||
| Q1 25 | -56.4% | 41.3% | ||
| Q4 24 | -71.3% | 34.0% | ||
| Q3 24 | -70.3% | 38.8% | ||
| Q2 24 | -109.6% | 37.9% |
| Q1 26 | 4.7% | 32.9% | ||
| Q4 25 | -18.9% | 32.3% | ||
| Q3 25 | 10.2% | 34.0% | ||
| Q2 25 | -43.5% | 32.3% | ||
| Q1 25 | -56.9% | 31.5% | ||
| Q4 24 | -71.0% | 26.0% | ||
| Q3 24 | -69.1% | 29.5% | ||
| Q2 24 | -107.0% | 28.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | $0.85 | ||
| Q3 25 | $0.06 | $0.86 | ||
| Q2 25 | $-0.17 | $0.79 | ||
| Q1 25 | $-0.20 | $0.75 | ||
| Q4 24 | $-0.22 | $0.59 | ||
| Q3 24 | $-0.22 | $0.68 | ||
| Q2 24 | $-0.31 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | — |
| Total DebtLower is stronger | — | $112.9M |
| Stockholders' EquityBook value | — | $670.9M |
| Total Assets | $505.9M | $6.5B |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | — | ||
| Q4 25 | $70.5M | $730.4M | ||
| Q3 25 | $55.0M | $695.6M | ||
| Q2 25 | $43.2M | $713.6M | ||
| Q1 25 | $50.6M | $756.1M | ||
| Q4 24 | $47.9M | $641.8M | ||
| Q3 24 | $38.1M | $523.0M | ||
| Q2 24 | $59.8M | $536.1M |
| Q1 26 | — | $112.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $670.9M | ||
| Q4 25 | $218.8M | $686.6M | ||
| Q3 25 | $204.4M | $692.0M | ||
| Q2 25 | $179.7M | $692.8M | ||
| Q1 25 | $190.4M | $687.8M | ||
| Q4 24 | $202.7M | $676.3M | ||
| Q3 24 | $223.8M | $669.0M | ||
| Q2 24 | $241.6M | $655.2M |
| Q1 26 | $505.9M | $6.5B | ||
| Q4 25 | $512.7M | $6.4B | ||
| Q3 25 | $490.6M | $6.3B | ||
| Q2 25 | $496.6M | $6.3B | ||
| Q1 25 | $510.9M | $6.3B | ||
| Q4 24 | $539.4M | $6.2B | ||
| Q3 24 | $558.5M | $6.1B | ||
| Q2 24 | $584.9M | $6.1B |
| Q1 26 | — | 0.17× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
Segment breakdown not available.
TRST
| Net Interest Income | $44.7M | 90% |
| Noninterest Income | $4.8M | 10% |
